Esperion's struggling-to-market, would-be blockbuster finds fresh infusion of cash
A year after winning approval for their heart disease pill, Esperion is still struggling to sell it.
Burned by a mid-pandemic launch, the Ann Arbor, MI-based biotech pocketed just $12.1 million last year on a drug they believed would one day be a blockbuster. Analysts expect a boost in Q1 but not a significant one — $11 to $12 million — and not enough to make their long-term balance sheet look particularly more attractive.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 105,400+ biopharma pros reading Endpoints daily — and it's free.